AZD 2479

Drug Profile

AZD 2479

Alternative Names: AVP 26452

Latest Information Update: 02 Apr 2007

Price : $50

At a glance

  • Originator Avanir Pharmaceuticals
  • Class Antihyperlipidaemics; Small molecules
  • Mechanism of Action Apolipoprotein A I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Atherosclerosis; Lipid metabolism disorders

Most Recent Events

  • 30 Mar 2007 Discontinued - Phase-I for Atherosclerosis in USA (PO)
  • 30 Mar 2007 Discontinued - Preclinical for Lipid metabolism disorders in USA (PO)
  • 30 Mar 2007 AstraZeneca and Avanir mutually agreed to end their research collaboration and license agreement on AZD 2479
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top